The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial

EuroIntervention 2010;6:813-818 - DOI10.4244/EIJV6I6A140.

1. The Heart Center, University Hospital Rigshospitalet, Copenhagen, Denmark; 2. Cardiology Department, Rabin Medical Center, Petah, Tikva, Israel; 3. Department of Cardiology, Universitätsklinik Munster, Munster, Germany; 4. Department of Cardiology, Ske

Aims: Genes encoding vascular endothelial growth factor (VEGF) can potentially augment myocardial perfusion in patients with coronary artery disease (CAD). We conducted a randomised, double

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Clinical results after coronary stenting with the GenousTM Bio-engineered R stentTM: 12-month outcomes of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry